[1]
|
H. Y. Luo, Y. H. Li, L. Zhang, W. Q. Jiang, Y. X. Shi, F. Wang, Y. J. He and R. H. Xu, “Efficacy of CPT-11 Combined 5-FU/CF (FOLFIRI) Regimen on Advanced Colorectal Cancer,” Chinese Journal of Cancer, Vol. 26, No. 8, 2007, pp. 905-908.
|
[2]
|
J. Li, “Application of Monoclonal Antibody in Combination with Irinotecan in the Treatment of Colorectal Cancer,” Chinese Journal of Oncology, Vol. 28, No. 10, 2006, pp. 796-797.
|
[3]
|
J. Ma, S. K. Qin and Q. Y. Zhang, “Album of Chinese Education in Clinical Oncology,” Heilongjiang Science and Technology Press, Haerbin, 2007, pp. 302-306.
|
[4]
|
S. P. Khosravi and P. I. Fernández, “Tumoral Angiogenesis: Review of the Literature,” Cancer Investigation, Vol. 26, No. 1, 2008, pp. 104-108.
doi:10.1080/07357900701662509
|
[5]
|
B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O’Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz and A. B. Benson, “Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200,” Journal of Clinical Oncology, Vol. 25, No. 12, 2007, pp. 1539-1544.
|
[6]
|
C. Emmanouilides, G. Sfakiotaki, N. Androulakis, K. Kalbakis, C. Christophylakis, A. Kalykaki, L. Vamvakas, A. Kotsakis, S. Agelaki, E. Diamandidou, N. Touroutoglou, A. Chatzidakis, V. Georgoulias, D. Mavroudis and J. Souglakos, “Front-Line Bevacizumab in Combination with Oxaliplatin, Leucovorin And 5-Fluorouracil (FOLFOX) in Patients with Metastatic Colorectal Cancer: A Multicenter Phase II Study,” BMC Cancer, Vol. 7, 2007, p. 91.
|
[7]
|
L. B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T. S. Yang, F. Rivera, F. Couture, F. Sirzén and J. Cassidy, “Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2013-2019.
|
[8]
|
H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. F. Novotny and F. Kabbinavar, “Bevacizumab in Combination with Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 23, No. 15, 2005, pp. 3502-3508.
|
[9]
|
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar, “Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” The New England Journal of Medicine, Vol. 350, 2004, pp. 2335-2342.
|
[10]
|
D. R. Gandara, R. Sangha and A. M. Davies, “Bevacizumab: Optimal Dose, Schedule, and Duration of Therapy,” Clinical Lung Cancer, Vol. 8, No. 9, 2007, pp. 522-523.
|
[11]
|
C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet and A. de Gramont, “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, 2004, pp. 229-237.
|